"Androgen Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
| Descriptor ID |
D000726
|
| MeSH Number(s) |
D06.347.065 D27.505.696.399.450.065
|
| Concept/Terms |
Anti-Androgen Effect- Anti-Androgen Effect
- Anti Androgen Effect
- Effect, Anti-Androgen
- Antiandrogen Effect
- Effect, Antiandrogen
- Antiandrogen Effects
- Effects, Antiandrogen
- Anti-Androgen Effects
- Anti Androgen Effects
- Effects, Anti-Androgen
|
Below are MeSH descriptors whose meaning is more general than "Androgen Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Androgen Antagonists".
This graph shows the total number of publications written about "Androgen Antagonists" by people in this website by year, and whether "Androgen Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 3 | 5 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 3 | 2 | 5 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 2 | 4 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 3 | 5 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 4 | 6 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 5 | 6 |
| 2024 | 3 | 3 | 6 |
| 2025 | 1 | 1 | 2 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Androgen Antagonists" by people in Profiles.
-
Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma. Nature. 2026 04; 652(8110):763-773.
-
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026 Jan; 37(1):53-68.
-
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115). Int J Radiat Oncol Biol Phys. 2025 Dec 01; 123(5):1247-1258.
-
Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. Cancer Med. 2024 Dec; 13(24):e70226.
-
Associations of SGLT2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy. Cardiovasc Drugs Ther. 2025 Dec; 39(6):1343-1352.
-
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216. Eur Urol Oncol. 2025 Jun; 8(3):612-615.
-
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. JAMA Netw Open. 2024 07 01; 7(7):e2419966.
-
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. 2024 Oct; 7(5):1097-1104.
-
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024 Sep; 27(3):507-519.
-
Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials. Int J Radiat Oncol Biol Phys. 2024 Jul 01; 119(3):826-831.